ER Membrane Phosphatidylethanolamine as a Rheostat for BCL-2/Beclin-1 Interaction and Autophagy in Aging

Ingrid Addo (DPhil)· Mar 26, 2026

Mechanism: In aged cells, high ER PE levels tightly bind BCL-2 and Beclin-1, suppressing autophagy and fueling inflammasome activation. Readout: Reducing ER PE disrupts this interaction, reactivating autophagy and dampening inflammation.

Hypothesis

Age‑dependent enrichment of phosphatidylethanolamine (PE) in the endoplasmic reticulum (ER) lumen promotes a tighter BCL‑2/Beclin‑1 complex, thereby suppressing autophagy and fueling inflammasome‑driven inflammation. Restoring ER PE homeostasis disrupts this interaction independent of canonical post‑translational modifications, re‑activating autophagy and breaking the autophagy‑inflammasome vicious cycle.

Mechanistic Rationale

BCL‑2’s ability to inhibit autophagy is restricted to its ER‑localized pool; mitochondrial BCL‑2 does not affect Beclin‑1 unless it binds AMBRA1【1】. This specificity suggests that ER‑resident lipids or protein partners modulate BCL‑2’s conformation or accessibility to Beclin‑1’s BH3 domain.
PE is a cone‑shaped phospholipid that promotes negative curvature and can alter the packing of transmembrane helices. Increased ER PE, reported in aged tissues due to altered phosphatidylserine decarboxylase activity, could favor a microenvironment where BCL‑2’s transmembrane domain adopts a conformation that enhances its cytosolic groove’s affinity for Beclin‑1.
Supporting this, lipid‑dependent regulation of Bcl‑2 family members has been observed at the mitochondria (e.g., cardiolipin binding to Bax), yet the analogous ER lipid code remains unexplored【2】.
If PE enrichment stabilizes the BCL‑2/Beclin‑1 complex, then reducing ER PE should mimic the effect of JNK1/ERK phosphorylation or TRAF6‑mediated ubiquitination that dissociates the pair【3】—but via a purely biophysical route.

Testable Predictions

Correlation: ER PE levels will be significantly higher in hepatocytes, fibroblasts, and macrophages from old (≥24 mo) mice compared with young (3 mo) counterparts.
Causality: Pharmacological or genetic reduction of ER PE (e.g., supplementation with ethanolamine kinase inhibitor or overexpression of phosphatidylethanolamine‑N‑methyltransferase) will decrease BCL‑2/Beclin‑1 co‑immunoprecipitation without altering total BCL‑2 or Beclin‑1 expression.
Functional Outcome: Reduced ER PE will increase LC3‑II/I ratio and p62 degradation, indicating enhanced autophagic flux, and concurrently lower NLRP3 inflammasome activation (reduced caspase‑1 cleavage and IL‑1β secretion) in aged cells.
In Vivo Rescue: Old mice treated with an ER‑targeted PE‑lowering agent will show improved autophagic markers in liver and kidney, diminished fibrosis, and extended median lifespan recapitulating the ~10‑12% gain seen with Beclin‑1 F121A mutation【4】.

Experimental Approach

Lipid Quantification: Isolate ER microsomes from young and old mouse tissues; quantify PE, phosphatidylcholine, and phosphatidylserine by LC‑MS/MS.
Interaction Assay: Perform co‑IP of BCL‑2 and Beclin‑1 from ER fractions ± PE‑modulating drugs (e.g., ethyl‑phosphocholine to inhibit PE synthesis). Include controls for BCL‑2/Bax binding to ensure specificity.
Autophagy Flux: Treat primary cultured cells with bafilomycin A1 and measure LC3 turnover by Western blot; use mCherry‑GFP‑LC3 reporter for autophagosome‑lysosome fusion.
Inflammasome Readout: Assay ASC speck formation and caspase‑1 activity after LPS/ATP stimulation.
In Vivo Study: Administer an ER‑targeted PE‑lowering peptide conjugate to aged mice for 6 months; monitor survival, histology (Sirius Red for fibrosis), and autophagy markers.

Potential Outcomes and Interpretation

If predictions hold: Elevated ER PE is a novel upstream regulator of the BCL‑2/Beclin‑1 axis; manipulating ER lipid composition offers a lipid‑centric strategy to reactivate autophagy in aging without directly inhibiting BCL‑2’s anti‑apoptotic function.
If ER PE does not correlate with BCL‑2/Beclin‑1 binding, or PE reduction fails to alter autophagy/inflammasome readouts, the hypothesis is falsified, directing focus back to protein‑centric mechanisms (phosphorylation, ubiquitination) or other ER‑resident regulators.

This hypothesis links membrane lipidomics to a well‑established protein interaction hub, providing a clear, falsifiable framework that can be addressed with existing biochemical, cell‑biological, and aging‑model tools.

Hypothesis

Mechanistic Rationale

BCL‑2’s ability to inhibit autophagy is restricted to its ER‑localized pool; mitochondrial BCL‑2 does not affect Beclin‑1 unless it binds AMBRA1【1】. This specificity suggests that ER‑resident lipids or protein partners modulate BCL‑2’s conformation or accessibility to Beclin‑1’s BH3 domain.

PE is a cone‑shaped phospholipid that promotes negative curvature and can alter the packing of transmembrane helices. Increased ER PE, reported in aged tissues due to altered phosphatidylserine decarboxylase activity, could favor a microenvironment where BCL‑2’s transmembrane domain adopts a conformation that enhances its cytosolic groove’s affinity for Beclin‑1.

Supporting this, lipid‑dependent regulation of Bcl‑2 family members has been observed at the mitochondria (e.g., cardiolipin binding to Bax), yet the analogous ER lipid code remains unexplored【2】.

If PE enrichment stabilizes the BCL‑2/Beclin‑1 complex, then reducing ER PE should mimic the effect of JNK1/ERK phosphorylation or TRAF6‑mediated ubiquitination that dissociates the pair【3】—but via a purely biophysical route.

Testable Predictions

Correlation: ER PE levels will be significantly higher in hepatocytes, fibroblasts, and macrophages from old (≥24 mo) mice compared with young (3 mo) counterparts.

Causality: Pharmacological or genetic reduction of ER PE (e.g., supplementation with ethanolamine kinase inhibitor or overexpression of phosphatidylethanolamine‑N‑methyltransferase) will decrease BCL‑2/Beclin‑1 co‑immunoprecipitation without altering total BCL‑2 or Beclin‑1 expression.

Functional Outcome: Reduced ER PE will increase LC3‑II/I ratio and p62 degradation, indicating enhanced autophagic flux, and concurrently lower NLRP3 inflammasome activation (reduced caspase‑1 cleavage and IL‑1β secretion) in aged cells.

In Vivo Rescue: Old mice treated with an ER‑targeted PE‑lowering agent will show improved autophagic markers in liver and kidney, diminished fibrosis, and extended median lifespan recapitulating the ~10‑12% gain seen with Beclin‑1 F121A mutation【4】.

Experimental Approach

Lipid Quantification: Isolate ER microsomes from young and old mouse tissues; quantify PE, phosphatidylcholine, and phosphatidylserine by LC‑MS/MS.

Interaction Assay: Perform co‑IP of BCL‑2 and Beclin‑1 from ER fractions ± PE‑modulating drugs (e.g., ethyl‑phosphocholine to inhibit PE synthesis). Include controls for BCL‑2/Bax binding to ensure specificity.

Autophagy Flux: Treat primary cultured cells with bafilomycin A1 and measure LC3 turnover by Western blot; use mCherry‑GFP‑LC3 reporter for autophagosome‑lysosome fusion.

Inflammasome Readout: Assay ASC speck formation and caspase‑1 activity after LPS/ATP stimulation.

In Vivo Study: Administer an ER‑targeted PE‑lowering peptide conjugate to aged mice for 6 months; monitor survival, histology (Sirius Red for fibrosis), and autophagy markers.

Potential Outcomes and Interpretation

If predictions hold: Elevated ER PE is a novel upstream regulator of the BCL‑2/Beclin‑1 axis; manipulating ER lipid composition offers a lipid‑centric strategy to reactivate autophagy in aging without directly inhibiting BCL‑2’s anti‑apoptotic function.

If ER PE does not correlate with BCL‑2/Beclin‑1 binding, or PE reduction fails to alter autophagy/inflammasome readouts, the hypothesis is falsified, directing focus back to protein‑centric mechanisms (phosphorylation, ubiquitination) or other ER‑resident regulators.